Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-30T23:51:00.375Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of severe depression with paroxetine

Published online by Cambridge University Press:  16 April 2020

J Tignol
J Tignol*
Affiliation:
Université de Bordeaux II, 121, rue de la Béchade, 33076Bordeaux, France
Get access

Summary

Meta-analyses of 417 patients diagnosed either prospectively (316 US patients) or retrospectively (101 European patients) as suffering from melancholia according to DSM III criteria have shown that paroxetine was significantly better than placebo with respect to all outcome measures. There was no significant difference between active control and placebo in these analyses. In a group of 216 severely depressed hospitalised patients with a HAMD score of 25 or more, paroxetine was as effective as active control.

Keywords

paroxetinemelancholiaHamilton Depression Rating Scale
Type
Research Article
Information
European Psychiatry , Volume 8 , Issue S1: New perspectives in the pharmacological treatment of depression. Defining the ideal antidepressant. 3 November 1992, Barcelona, Spain , 1993 , pp. 21s - 23s
Copyright
Copyright © Elsevier, Paris 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Dunbar, GCStoker, MJ (1991) Paroxetine in the treatment of severe (melancholic) depression. Paper presented at the 5th World Cong Biol Psychiatry, June 9–14Google Scholar
Submit a response

Comments

No Comments have been published for this article.